Date: 2013-10-19
Type of information: Initiation of the trial
phase: 1-2
Announcement: initiation of the trial
Company: Merck KGaA (Germany)
Product: tepotinib
Action
mechanism: tyrosine kinase inhibitor. Tepotinib is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase that has been shown to cause growth inhibition and regression of tumors in preclinical models. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis.
Disease: non-small cell lung cancer
Therapeutic area: Cancer - Oncology
Country: Germany
Trial
details: This is a multi-center, open-label, randomized, Phase 1b/2 trial to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of MSC2156119J when used in combination with gefitinib in subjects with T790M negative, MET positive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and having acquired resistance to Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy. (NCT01982955)
Latest
news: * On October 29, 2013, a Phase 1-2 trial sponsored by Merck KGaA was published on the NIH website ClinicalTrials.gov for tepotinib and is currently recruiting participants.
